Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) Acute Myeloid Leukemia (AML).
The specific purpose of this study is to: Find out what effects, good and bad, the study drug, CPX-351, has on participants with newly diagnosed high risk (secondary) leukemia. To compare survival among participants with high risk (secondary) leukemia who receive the study drug with those who receive the standard treatment, “7+3”, Cytarabine and Daunorubicin.
Untreated High Risk (Secondary) Acute Myeloid Leukemia (AML)
60-75 Years of Age with Untreated High Risk (Secondary) Acute Myeloid Leukemia (AML)
60 - 75
Healthy Volunteers Needed
Duration of Participation
During the first year the participant will be seen on a monthly basis in clinic. After the first year, the participant will be contacted regularly to see how their leukemia is and if they have received any new leukemia medications. The participants will be followed for up to 5 years from study randomization.
Nan Subbiah 503-494-4603
Celator Pharmaceuticals Inc.